Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 1
1983 2
1984 3
1985 2
1988 4
1989 6
1990 3
1991 1
1992 4
1993 3
1994 4
1995 5
1996 6
1997 8
1998 5
1999 1
2000 2
2001 2
2002 3
2004 1
2009 2
2010 2
2011 8
2012 1
2014 1
2015 2
2016 2
2017 5
2018 3
2019 2
2020 1
2021 1
2022 1
2023 1
2024 2
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Results by year

Filters applied: . Clear all
Page 1
Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study.
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Casulo C, et al. Among authors: farber cm. J Clin Oncol. 2015 Aug 10;33(23):2516-22. doi: 10.1200/JCO.2014.59.7534. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124482 Free PMC article.
Sulfadiazine revisited.
Ventura MG, Wybran J, Farber CM. Ventura MG, et al. Among authors: farber cm. J Infect Dis. 1989 Sep;160(3):556-7. doi: 10.1093/infdis/160.3.556. J Infect Dis. 1989. PMID: 2760508 No abstract available.
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.
Treon SP, Kotton CN, Park DJ, Moranzoni G, Lemvigh CK, Gathe JC Jr, Varughese TA, Barnett CF, Belenchia JM, Clark NM, Farber CM, Abid MB, Ahmed G, Patterson CJ, Guerrera ML, Soumerai JD, Chea VA, Carulli IP, Southard J, Li S, Wu CJ, Livak KJ, Holmgren E, Kim P, Shi C, Lin H, Ramakrishnan V, Ou Y, Olszewski S, Olsen LR, Keskin DB, Hunter ZR, Tankersley C, Zimmerman T, Dhakal B. Treon SP, et al. Among authors: farber cm. Front Immunol. 2025 Jan 21;15:1369619. doi: 10.3389/fimmu.2024.1369619. eCollection 2024. Front Immunol. 2025. PMID: 39906744 Free PMC article. Clinical Trial.
Treatment of Peripheral T-Cell Lymphoma in Community Settings.
Feldman T, Farber CM, Choi K, Faria C, Goy A, Connors J, Paramanathan D, Kaur S, Schultz E, McGuire M, Goldberg SL. Feldman T, et al. Among authors: farber cm. Clin Lymphoma Myeloma Leuk. 2017 Jun;17(6):354-361. doi: 10.1016/j.clml.2017.05.001. Epub 2017 May 10. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28622960
Substitution therapy for C1 esterase deficiency.
Farber CM, Gourdin A, Lambermont M, Gilbert C, Van Vooren JP. Farber CM, et al. Lancet. 1992 Jan 11;339(8785):119. doi: 10.1016/0140-6736(92)91023-2. Lancet. 1992. PMID: 1345835 No abstract available.
99 results